Gold Gains 1%; US Home-Builder Sentiment Edges Higher In August

argenx Completes Acquisition of Forte Biosciences, Inc.

argenx successfully completed its acquisition of Forte Biosciences for $77.00 per share in cash, adding FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease. The acquisition expands argenx's immunology portfolio and supports its Vision 2030 strategy to become a leading immunology innovation company by targeting diseases with limited treatment options.

argenx shares are trading higher after UBS upgraded its rating on the stock from Neutral to Buy and raised its price target from $960 to $1400. Also, Wells Fargo maintained its Overweight rating and raised its price target from $1350 to $1415.

UBS Upgrades argenx to Buy, Raises Price Target to $1400

Wells Fargo Maintains Overweight on argenx, Raises Price Target to $1415

Wells Fargo analyst Derek Archila maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $1350 to $1415.

Enovix Accelerates South Korea Capacity Expansion To Double Drone Battery Output And Advance MX‑1 Silicon‑Blended Platform

Enovix Corporation (NASDAQ:ENVX) ("Enovix"), a developer and manufacturer of advanced lithium-ion batteries, including proprietary silicon-anode architectures, today provided additional details of its

Why Kulicke & Soffa Stock Slumped by Nearly 10% Today

Kulicke & Soffa Industries stock fell nearly 10% after announcing Raj Talluri as its new permanent CEO, replacing interim CEO Lester Wong. The decline appears driven by concerns over the lengthy succession process in a fast-moving industry and profit-taking following strong Q3 earnings. Analyst expects the stock to rebound.